

DAFTAR PUSTAKA

- Al-Gobari, M., Al-Aqeel, S., Gueyffier, F., & Burnand, B. (2018). Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: An overview of systematic reviews. *BMJ Open*, 8(7), e021108. <https://doi.org/10.1136/bmjopen-2017-021108>
- Aljuaid, A. S., Alharthi, T. M., Alzahrani, T. A. M., Aljabir, A. S. A., Almontashiri, A. H., Ali, S. A., Aljuaeed, M. S. A., Alzilfi, Y. A., Mohamed, G., & Elnemr, H. (2018). SACUBITRIL/ VALSARTAN CLINICAL OUTCOMES IN HEART FAILURE PATIENTS; A SYSTEMATIC REVIEW. *INDO AMERICAL JOURNAL OF PHARMACEUTICAL SCIENCES*, 05(12), 14227–14233. <https://doi.org/10.5281/zenodo.1973898>
- Allredge, B. K. (2013). *Applied Therapeutics: The Clinical Use of Drugs* (M. A. Koda-Kimble, Ed.; 10th ed). Wolters Kluwer/Lippincott Williams & Wilkins.
- Allen, L. A., & Spertus, J. A. (2013). End Points for Comparative Effectiveness Research in Heart Failure. *Heart Failure Clinics*, 9(1), 15–28. <https://doi.org/10.1016/j.hfc.2012.09.002>
- Ambrosy, A. P., Vaduganathan, M., Mentz, R. J., Greene, S. J., Subačius, H., Konstam, M. A., Maggioni, A. P., Swedberg, K., & Gheorghide, M. (2013). Clinical Profile and Prognostic Value of Low Systolic Blood Pressure in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. *American Heart Journal*, 165(2), 216–225. <https://doi.org/10.1016/j.ahj.2012.11.004>
- Balmforth, C., Simpson, J., Shen, L., Jhund, P. S., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V., Solomon, S. D., Swedberg, K., Zile, M. R., Packer, M., & McMurray, J. J. V. (2019). Outcomes and Effect of Treatment According to Etiology in HFrEF. *JACC: Heart Failure*, 7(6), 457–465. <https://doi.org/10.1016/j.jchf.2019.02.015>

- Böhm, M., Young, R., Jhund, P. S., Solomon, S. D., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Packer, M., & McMurray, J. J. V. (2017). Systolic Blood Pressure, Cardiovascular Outcomes and Efficacy and Safety of Sacubitril/Valsartan (LCZ696) in Patients with Chronic Heart Failure and Reduced Ejection Fraction: Results from PARADIGM-HF. *European Heart Journal*, *38*(15), 1132–1143. <https://doi.org/10.1093/eurheartj/ehw570>
- Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J. V., O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D., Rouleau, J. L., & for the PARADIGM-HF Investigators and Committees. (2018). Growth Differentiation Factor-15 is Not Modified by Sacubitril/Valsartan and is An Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF trial. *European Journal of Heart Failure*, *20*(12), 1701–1709. <https://doi.org/10.1002/ejhf.1301>
- Bratsos, S. (2019). Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Nepriylsin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials. *Cureus*. <https://doi.org/10.7759/cureus.3913>
- Buggey, J., Mentz, R. J., DeVore, A. D., & Velazquez, E. J. (2015). Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. *Journal of Cardiac Failure*, *21*(9), 741–750. <https://doi.org/10.1016/j.cardfail.2015.07.008>
- Campbell, D. J. (2017). Long-term Neprilysin Inhibition—Implications for ARNIs. *Nature Reviews Cardiology*, *14*(3), 171–186. <https://doi.org/10.1038/nrcardio.2016.200>
- Chandra, A., Lewis, E. F., Claggett, B. L., Desai, A. S., Packer, M., Zile, M. R., Swedberg, K., Rouleau, J. L., Shi, V. C., Lefkowitz, M. P., Katova, T., McMurray, J. J. V., & Solomon, S. D. (2018). Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. *JAMA Cardiology*, *3*(6), 498–505. PubMed. <https://doi.org/10.1001/jamacardio.2018.0398>

- Chaplin, S. (2016). Sacubitril/valsartan for Chronic Heart Failure: Its Future Potential: Sacubitril/Valsartan. *Prescriber*, 27(11), 26–34. <https://doi.org/10.1002/psb.1514>
- Collier, T. J., Pocock, S. J., McMurray, J. J. V., Zannad, F., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2013). The Impact of Eplerenone at Different Levels of Risk in Patients with Systolic Heart Failure and Mild Symptoms: Insight From A Novel Risk Score for Prognosis Derived From The EMPHASIS-HF trial. *European Heart Journal*, 34(36), 2823–2829. <https://doi.org/10.1093/eurheartj/ehv247>
- Dargad, R. R., Prajapati, M. R., Dargad, R. R., & Parekh, J. D. (2018). Sacubitril/Valsartan: A Novel Angiotensin Receptor-Nepriylsin Inhibitor. *Indian Heart Journal*, 70, S102–S110. <https://doi.org/10.1016/j.ihj.2018.01.002>
- Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., & Solomon, S. D. (2015). Effect of The Angiotensin-Receptor-Nepriylsin Inhibitor LCZ696 Compared With Enalapril on Mode Of Death in Heart Failure Patients. *European Heart Journal*, 36(30), 1990–1997. <https://doi.org/10.1093/eurheartj/ehv186>
- Dézi, C. A. (2014). Differences in the Clinical Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Critical Review of the Evidence. *American Journal of Cardiovascular Drugs*, 14(3), 167–173. <https://doi.org/10.1007/s40256-013-0058-8>
- Ellahham, S. (2018). Sacubitril/Valsartan in Management of Heart Failure: A Review of Safety, Efficacy and Cost-Effectiveness. *Cardiovascular Pharmacology: Open Access*, 07(06). <https://doi.org/10.4172/2329-6607.1000250>
- Fröhlich, H., Henning, F., Täger, T., Schellberg, D., Grundtvig, M., Goode, K., Corletto, A., Kazmi, S., Hole, T., Katus, H. A., Atar, D., Cleland, J. G. F., Agewall, S., Frankenstein, L., & Clark, A. L. (2018). Comparative

effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: A propensity score-matched cohort study. *European Heart Journal - Cardiovascular Pharmacotherapy*, 4(2), 82–92. <https://doi.org/10.1093/ehjcvp/pvx013>

George, M., Jena, A., Srivatsan, V., Muthukumar, R., & Dhandapani, V. (2016). GDF 15—A Novel Biomarker in the Offing for Heart Failure. *Current Cardiology Reviews*, 12(1), 37–46. <https://doi.org/10.2174/1573403X12666160111125304>

Hariyati, R. T. S. (2010). Mengenal Sistematis Review Theory dan Studi Kasus. *Jurnal Keperawatan Indonesia*, 13(2), 9.

Jhund, P. S., Fu, M., Bayram, E., Chen, C.-H., Negrusz-Kawecka, M., Rosenthal, A., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., McMurray, J. J. V., & Packer, M. (2015). Efficacy and Safety of LCZ696 (Sacubitril-Valsartan) According to Age: Insights from PARADIGM-HF. *European Heart Journal*, 36(38), 2576–2584. <https://doi.org/10.1093/eurheartj/ehv330>

Kemenkes RI. (2013). *Riset Kesehatan Dasar; RISKESDAS*. Balitbang.

Kemenkes RI. (2018). *Riset Kesehatan Dasar; RISKESDAS*. Balitbang.

Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., Riegger, G. A., Malbecq, W., Smith, R. D., Gupta, S., & Poole-Wilson, P. A. (2009). Effects of High-Dose versus Low-Dose Losartan on Clinical Outcomes In Patients With Heart Failure (HEAAL Study): A Randomised, Double-Blind Trial. *The Lancet*, 374(9704), 1840–1848. [https://doi.org/10.1016/S0140-6736\(09\)61913-9](https://doi.org/10.1016/S0140-6736(09)61913-9)

Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., McMurray, J. J. V., & Packer, M. (2016). Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure

- Trial. *Circulation: Heart Failure*, 9(1).
<https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560>
- Krive, J., Shoolin, J. S., & Zink, S. D. (2014). *Effectiveness of Evidence-Based Congestive Heart Failure (CHF) CPOE Order Sets Measured by Health Outcomes*. 10.
- Leonard, L. (Ed.). (2016). *Pathophysiology of Heart Disease, Sixth Edition*. Wolters Kluwer.
- Li, B., Zhao, Y., Yin, B., Helian, M., Wang, X., Chen, F., Zhang, H., Sun, H., Meng, B., & An, F. (2017). Safety of The Neprilysin/Renin-Angiotensin System Inhibitor LCZ696. *Oncotarget*, 8(47).
<https://doi.org/10.18632/oncotarget.18312>
- Malik, A. H., & Aronow, W. S. (2019). Efficacy of Sacubitril/Valsartan in Hypertension. *American Journal of Therapeutics, Publish Ahead of Print*.
<https://doi.org/10.1097/MJT.0000000000000925>
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R. (2014). Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. *New England Journal of Medicine*, 371(11), 993–1004.
<https://doi.org/10.1056/NEJMoa1409077>
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., & on behalf of the PARADIGM-HF Committees and Investigators. (2013). Dual Angiotensin Receptor and Neprilysin Inhibition as An Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale For and Design of The Prospective Comparison Of ARNI with ACEI to Determine Impact. *European Journal of Heart Failure*, 15(9), 1062–1073.
<https://doi.org/10.1093/eurjhf/hft052>
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., & on behalf of the PARADIGM-HF Committees Investigators. (2014). Baseline Characteristics and Treatment of Patients in Prospective

- Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). *European Journal of Heart Failure*, 16(7), 817–825. <https://doi.org/10.1002/ejhf.115>
- Menendez, J. T. (2016). The Mechanism of Action of LCZ696 [Review of *The Mechanism of Action of LCZ696*, by Department of Pharmacology, School of Medicine, University Complutense, Madrid, Spain]. *Cardiac Failure Review*, 2(1), 40. <https://doi.org/10.15420/cfr.2016:1:1>
- Mogensen, U. M., Gong, J., Jhund, P. S., Shen, L., Køber, L., Desai, A. S., Lefkowitz, M. P., Packer, M., Rouleau, J. L., Solomon, S. D., Claggett, B. L., Swedberg, K., Zile, M. R., Mueller-Velten, G., & McMurray, J. J. V. (2018). Effect of Sacubitril/Valsartan on Recurrent Events in The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF): Effect Of Sacubitril/Valsartan on Recurrent Events. *European Journal of Heart Failure*, 20(4), 760–768. <https://doi.org/10.1002/ejhf.1139>
- Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., & McMurray, J. J. V. (2016a). Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). *Circulation*, 133(23), 2254–2262. <https://doi.org/10.1161/CIRCULATIONAHA.115.020729>
- Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., & McMurray, J. J. V. (2016b). Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. *Circulation: Heart Failure*, 9(9). <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003212>
- Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M.,

- Andersen, K., Arango, J. L., Arnold, J. M., Bělohlávek, J., Böhm, M., Boytsov, S., Burgess, L. J., Cabrera, W., ... Wong, R. C.-C. (2015). Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. *Circulation*, *131*(1), 54–61. <https://doi.org/10.1161/CIRCULATIONAHA.114.013748>
- Pranata, S. (2017). The Effect of Transcutaneous Electrical Nerve Stimulation (Tens) Towards Wound Healing. *Nurscope: Jurnal Penelitian dan Pemikiran Ilmiah Keperawatan*, *2*(2), 1. <https://doi.org/10.30659/nurscope.2.2.1-12>
- Ramdhani, A., Ramdhani, M. A., & Amin, A. S. (2014). Writing a Literature Review Research Paper: A step-by-step approach. *International Journal of Basic and Applied Science*, *03*(01), 10.
- Ruilope, L. M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J., & Lefkowitz, M. P. (2010). Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. *The Lancet*, *375*(9722), 1255–1266. [https://doi.org/10.1016/S0140-6736\(09\)61966-8](https://doi.org/10.1016/S0140-6736(09)61966-8)
- Sari, P. R., Rampengan, S. H., & Panda, A. L. (2013). Hubungan Kelas NYHA dengan Fraksi Ejeksi pada Pasien Gagal Jantung Kronik di BLU/RSUP Prof. Dr. R.D. Kandou Manado. *e-CliniC*, *1*(2). <https://doi.org/10.35790/ecl.1.2.2013.3266>
- Sartipy, U., Dahlström, U., Edner, M., & Lund, L. H. (2014). Predicting Survival in Heart Failure: Validation of The MAGGIC Heart Failure Risk Score in 51 043 Patients From The Swedish Heart Failure Registry: Validation of The MAGGIC Heart Failure Risk Score in 51 043 Patients. *European Journal of Heart Failure*, *16*(2), 173–179. <https://doi.org/10.1111/ejhf.32>
- Savarese, G., Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, Lund, L. H., Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, & Department of Cardiology, Karolinska University Hospital,

- Stockholm, Sweden. (2017). Global Public Health Burden of Heart Failure. *Cardiac Failure Review*, 03(01), 7. <https://doi.org/10.15420/cfr.2016:25:2>
- Savarese, G., Edner, M., Dahlström, U., Perrone-Filardi, P., Hage, C., Cosentino, F., & Lund, L. H. (2015). Comparative Associations Between Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Their Combination, and Outcomes in Patients with Heart Failure and Reduced Ejection Fraction. *International Journal of Cardiology*, 199, 415–423. <https://doi.org/10.1016/j.ijcard.2015.07.051>
- Simpson, J., Jhund, P. S., Silva Cardoso, J., Martinez, F., Mosterd, A., Ramires, F., Rizkala, A. R., Senni, M., Squire, I., Gong, J., Lefkowitz, M. P., Shi, V. C., Desai, A. S., Rouleau, J. L., Swedberg, K., Zile, M. R., McMurray, J. J. V., Packer, M., & Solomon, S. D. (2015). Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. *Journal of the American College of Cardiology*, 66(19), 2059–2071. <https://doi.org/10.1016/j.jacc.2015.08.878>
- Siswanto, B., Hersunarti, N., Erwinanto, & Barack, R. (2015). *Pedoman Tatalaksana Gagal Jantung*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Snyder, H. (2019). Literature Review as A Research Methodology: An Overview and Guidelines. *Journal of Business Research*, 104, 333–339. <https://doi.org/10.1016/j.jbusres.2019.07.039>
- Solomon, S. D., Claggett, B., Desai, A. S., Packer, M., Zile, M., Swedberg, K., Rouleau, J. L., Shi, V. C., Starling, R. C., Kozan, Ö., Dukat, A., Lefkowitz, M. P., & McMurray, J. J. V. (2016). Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circulation: Heart Failure*, 9(3). <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744>

- Solomon, S. D., Claggett, B., Packer, M., Desai, A., Zile, M. R., Swedberg, K., Rouleau, J., Shi, V., Lefkowitz, M., & McMurray, J. J. V. (2016). Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation. *JACC: Heart Failure*, 4(10), 816–822. <https://doi.org/10.1016/j.jchf.2016.05.002>
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., ... Lefkowitz, M. P. (2019). Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*, 381(17), 1609–1620. <https://doi.org/10.1056/NEJMoa1908655>
- Tai, C., Gan, T., Zou, L., Sun, Y., Zhang, Y., Chen, W., Li, J., Zhang, J., Xu, Y., Lu, H., & Xu, D. (2017). Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Cardiovascular Events in Patients with Heart Failure: A Meta-Analysis of Randomized Controlled Trials. *BMC Cardiovascular Disorders*, 17(1), 257. <https://doi.org/10.1186/s12872-017-0686-z>
- Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., Yee, R., Healey, J. S., & Rouleau, J. L. (2010). Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. *New England Journal of Medicine*, 363(25), 2385–2395. <https://doi.org/10.1056/NEJMoa1009540>
- The SOLVD Investigators*, Yusuf, Salim, Pitt, Bertram, Davis, Clarence, Hood, William, & Cohn, Jay. (1991). Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. *New England Journal of Medicine*, 325(5), 293–302. <https://doi.org/10.1056/NEJM199108013250501>
- Van Spall, H. G. C., Rahman, T., Mytton, O., Ramasundarahettige, C., Ibrahim, Q., Kabali, C., Coppens, M., Brian Haynes, R., & Connolly, S. (2017). Comparative Effectiveness of Transitional Care Services in Patients Discharged from The Hospital with Heart Failure: A Systematic Review and Network Meta-Analysis: Comparative Effectiveness of Transitional

- Care Services in Patients Hospitalized with Heart Failure. *European Journal of Heart Failure*, 19(11), 1427–1443. <https://doi.org/10.1002/ejhf.765>
- Vardeny, O., Claggett, B., Packer, M., Zile, M. R., Rouleau, J., Swedberg, K., Teerlink, J. R., Desai, A. S., Lefkowitz, M., Shi, V., McMurray, J. J. V., Solomon, S. D., & for the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. (2016). Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF Trial. *European Journal of Heart Failure*, 18(10), 1228–1234. <https://doi.org/10.1002/ejhf.580>
- Vardeny, O., Miller, R., & Solomon, S. D. (2014). Combined Nephilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. *JACC: Heart Failure*, 2(6), 663–670. <https://doi.org/10.1016/j.jchf.2014.09.001>
- Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Khan, S. S., Kissela, B. M., Knutson, K. L., Kwan, T. W., Lackland, D. T., ... On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. (2020). Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. *Circulation*, 141(9). <https://doi.org/10.1161/CIR.0000000000000757>
- Volz, A., Schmid, J.-P., Zwahlen, M., Kohls, S., Saner, H., & Barth, J. (2011). Predictors of Readmission and Health Related Quality of Life in Patients with Chronic Heart Failure: A Comparison of Different Psychosocial Aspects. *Journal of Behavioral Medicine*, 34(1), 13–22. <https://doi.org/10.1007/s10865-010-9282-8>
- Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J.

J. V., Mitchell, J. E., Peterson, P. N., Riegel, B., ... Wilkoff, B. L. (2013). 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*, 62(16), e147–e239. <https://doi.org/10.1016/j.jacc.2013.05.019>

Yancy, C. W., WRITING COMMITTEE MEMBERS, Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G., Fonarow, G. C., Givertz, M. M., Hollenberg, S. M., Lindenfeld, J., Masoudi, F. A., McBride, P. E., Peterson, P. N., Stevenson, L. W., & Westlake, C. (2016). 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*, 134(13). <https://doi.org/10.1161/CIR.0000000000000435>

Yandrapalli, S., Aronow, W. S., Mondal, P., & Chabbott, D. R. (2017). Limitations of Sacubitril/Valsartan in the Management of Heart Failure. *American Journal of Therapeutics*, 24(2), e234–e239. <https://doi.org/10.1097/MJT.0000000000000473>